Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by nemo3on Apr 26, 2019 10:16am
117 Views
Post# 29674183

Slowly marching forward

Slowly marching forwardWe have a long road ahead till phase 2 is completed. Hopefully results will be a very high efficacy rate. News yesterday certainly didn't do much so I wonder if this won't trend downwards into the 40s or high 30s while we wait for trial results. There seems to be some competition and first to market can be a significant factor in success. Just my idle thoughts as I hold and wait for results over the next year and two. I also wonder if they go the route of just licensing this to various centers, then it wouldn't be too much of a boost to the share price. I would love to see a high valuation if this trial succeeds with a high efficacy rate. Have no idea what that price would be tho. Would we.be looking at $2 to $5...or would this be $30 to $50. Well...onwards and hopefully many cancer patients will one day be alive due to TLT.
Bullboard Posts